Skip to main content

Table 4 Association values between genotypes and metabolizer phenotypes

From: A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

Association values between genotypes and the slow metabolizer phenotype using dominant, recessive and additive models

Gene

Polymorphism

Model

OR (95 % CI)

P-Value

Pc Value

MTHFR

rs1801133

Dominant (C/C vs. C/T + T/T)

C/T + T/T = 0.64 (0.42–0.99)*

0.011

0.028**

   

C/C = 3.11 (1.26–7.68)*

  

DRD3

rs6280

Recessive (C/C + C/T vs. T/T)

C/C + C/T = 0.62 (0.38–1.00)

0.015

0.034**

   

T /T = 2.63 (1.21–5.70)*

  

GSTM3

rs1799735

Additive (*A/*A vs. *A/*B)

*A/*A = 0.88 (0.70–1.09)

0.126

0.308

   

*A/*B = 3.50 (0.64–19.20)

  

TNF

rs1800629

Additive (G/G vs. G/A)

G/G = 0.89 (0.68–1.16)

0.324

0.553

   

G/A = 1.82 (0.55–6.00)

  

MDR1

rs1045642

Dominant (C/C vs. C/T + T/T)

C/T + T/T = 1.45 (1.18–1.77)*

0.008

0.020**

   

C/C = 0.06 (0.003–1.00)

  

SLCO1B1

rs4149056

Recessive (C/C + C/T vs. T/T)

C/C + C/T = 1.33 (0.45–3.99)

0.610

0.884

   

T/T = 0.93 (0.70–1.23)

  
  1. OR odds ratio, CI confidence interval, Pc P-values adjusted by using Bonferroni’s correction for multiple comparisons, − = Not calculated, ** = P ≤ 0.05. Clusters are explained in the main text